pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,098 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints609BioPharma Dive235onclive165Fierce Biotech79BioSpace78raps32globenewswire health24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
    The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
    STAT · 5d ago↗ source
  • U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
    Federal health officials are investigating a new outbreak involving the diarrhea-causing parasite cyclospora.
    STAT · 5d ago↗ source
  • STAT+: European regulators take steps to bolster clinical trial transparency
    The European Medicines Agency is taking what advocacy groups are calling unexpectedly “rapid action” to ensure that clinical trial results are made public as required by law.
    STAT · 6d ago↗ source
← prev
page 4 of 44
next →
fda recalls20
fda press20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Popular insulin product enters shortage as other pens leave market
    The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
    STAT · 6d ago↗ source
  • Senate health panel delays vote on CDC nominee
    Too few senators were in attendance to proceed with a vote on the CDC director nominee.
    STAT · 6d ago↗ source
  • Lilly, with new data, to seek FDA approval of obesity drug retatrutide
    The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
    BioPharma Dive · 6d ago↗ source
  • STAT+: What’s in the last-minute flurry of health care bills?
    Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior authorization top the list.
    STAT · 6d ago↗ source
  • FDA panel confronting peptide controversy
    Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
    STAT · 6d ago↗ source
  • A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
    Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare disease? Find out on this week's episode of…
    STAT · 6d ago↗ source
  • STAT+: Vote on key federal health nominee delayed amid questions over vaccine views
    Sean Kaufman, nominated to run ASPR, has a track record of questioning the safety of vaccines.
    STAT · 6d ago↗ source
  • STAT+: Trump administration quietly picks Timothy Westlake to lead mental health agency
    Timothy Westlake, an emergency doctor nominated to head SAMHSA, has been active in addiction policy in Wisconsin.
    STAT · 6d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
    A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
    STAT · 6d ago↗ source
  • STAT+: HHS to convene experts on standards for clinical AI
    In this edition of STAT Health Tech: HHS is inviting experts to shape policy on clinical AI, Whoop's new CMO, news about brain implants, and more.
    STAT · 6d ago↗ source
  • STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
    A leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.
    STAT · 6d ago↗ source
  • Expect a clash at today’s FDA peptide panel
    The service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning Rounds
    STAT · 6d ago↗ source
  • STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
    On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
    STAT · 6d ago↗ source
  • Filing of bipartisan Senate bill boosts momentum for office of men’s health
    Mirroring the bipartisan bill introduced in the House, the measure would require a study from the GAO on the state of men’s health in the U.S. to be presented within…
    STAT · 6d ago↗ source
  • STAT+: Trump promised redemption for troops who refused Covid shots. A year later, many are still waiting
    Veterans who want to rejoin the military are often bogged down in bureaucratic red tape.
    STAT · 6d ago↗ source
  • Opinion: New billing codes likely to raise maternity care costs
    “This change is likely to lead to only modest increases in total medical expenses. However, it coincides with many other factors raising health insurance premiums,” writes Jeff Levin-Scherz.
    STAT · 6d ago↗ source
  • Opinion: Good riddance to bundled ‘global’ maternal care billing
    New maternal billing codes should create a transparent system where both patients and clinicians can thrive, ACOG writes.
    STAT · 6d ago↗ source
  • STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
    FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
    STAT · 6d ago↗ source
  • Recon: J&J nabs FDA authorization for general surgery robot; FDA urged to ban DTC drug ads
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 6d ago↗ source
  • Euro Roundup: EMA seeks feedback on planned changes to guidance on biosimilar efficacy studies
    The European Medicines Agency (EMA) has released a draft concept paper on planned changes to its guideline on similar biological medicinal products.
    raps · 6d ago↗ source
  • Study: Most sponsors complete postmarketing trials, publish results
    Postmarketing requirements and commitments were completed for nearly nine out of ten drugs approved by the US Food and Drug Administration, with such requirements or commitments assigned at the tim…
    raps · 6d ago↗ source
  • FDA advisory committee backs two controversial peptides
    An advisory committee to the US Food and Drug Administration (FDA) voted 8-6 with one abstention on Thursday to recommend that two peptides – BPC-157 to treat ulcerative colitis and KPV for wound t…
    raps · 6d ago↗ source